You are in: eMedicine Specialties > Sports Medicine > Lower Limb Osgood-Schlatter DiseaseArticle Last Updated: Apr 28, 2006AUTHOR AND EDITOR INFORMATIONAuthor: Munisha Mehra Bhatia, MD, General Academic Pediatrics, Faculty Development Fellow, Children's Memorial Hospital of Northwestern University Munisha Mehra Bhatia is a member of the following medical societies: Ambulatory Pediatric Association and American Academy of Pediatrics Coauthor(s): Janos P Ertl, MD, Clinical Assistant Professor, Department of Orthopedic Surgery, Chief of Orthopedic Trauma, University of California at Davis; Director of Amputee Clinic, Kaiser Hospital; Gyorgy Kovacs, MD, Department of Orthopedic Surgery, Consulting Surgeon, GOC Clinic Editors: Andrew L Sherman, MD, Associate Professor, Departments of Neurological Surgery, Orthopedics, and Rehabilitation, University of Miami Miller School of Medicine; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Marlene DeMaio, MD, Consulting Staff, Department of Orthopedic Surgery, Assistant Professor, Bone & Joint/Sports Medicine Institute, Naval Medical Center; Jon Whitehurst, MD, Consulting Staff, Rockford Orthopedic Associates; William Jay Bryan, MD, Clinical Professor, Department of Orthopedic Surgery, Baylor University College of Medicine Author and Editor Disclosure Synonyms and related keywords: OSD, tibial tubercle osteochondrosis, traction apophysitis, knee pain INTRODUCTIONBackgroundIn 1903, Robert Osgood (1873-1956), a US orthopedic surgeon, and Carl Schlatter (1864-1934), a Swiss surgeon, concurrently described the disease that now bears their names. Osgood-Schlatter disease (OSD) is one of the most common causes of knee pain in active adolescents. FrequencyUnited StatesOSD affects 20% of athletic adolescents, as compared with the frequency of 4.5% of age-matched nonathletic controls. The disease is bilateral in 20-50% of patients. Boys are affected more commonly than girls, with a male-to-female ratio of 3:1. Boys aged 10-15 years and girls aged 8-13 years typically are affected, coinciding with growth spurts. Functional AnatomyIn girls younger than 11 years and in boys younger than 13 years, the tibial tubercle consists of cartilaginous tissue. The secondary ossification center or apophysis of the tibial tubercle develops when girls are aged 8-12 years and when boys are aged 9-13 years. During this stage of skeletal development, the Osgood-Schlatter lesion may occur. The most commonly accepted theory is that repeated traction (traction apophysitis) on the anterior portion of this developing ossification center leads to multiple subacute fractures or tendinous inflammation, resulting in a benign self-limited disturbance manifested as pain, swelling, and tenderness. By the end of the ensuing 2 stages of bony development (eg, epiphyseal and bony stages), the growth plates of the proximal tibia fuse in both males and females (usually when aged 14-18 y) and the OSD usually subsides. Sport Specific BiomechanicsDuring running, gymnastics, and other sports requiring repeated contractions of the quadriceps, an extra-articular osteochondral stress fracture or microavulsion occurs. The proximal area of the patellar tendon insertion separates, resulting in elevation of the tibial tubercle. During the reparative phase of this stress fracture, new bone is laid down in the avulsion space, which may result in a deviated and prominent tibial tubercle. When an individual with an injured tibial tubercle continues to participate in sports, more and more microavulsions develop, and the reparative process may result in a markedly pronounced prominence of the tubercle with longer-term cosmetic and functional implications. A separated fragment may develop at the patellar tendon insertion and may lead to chronic nonunion-type pain. CLINICALHistory
PhysicalThe physical examination is very specific with point tenderness over the tibial tubercle. Other physical examination findings may include the following:
CausesThe cause of OSD is unknown; however, theories suggest that this condition is a result of repeated knee extensor mechanism contraction that causes partial avulsions or microavulsions of the chondrofibroosseous tibial tubercle. OSD usually occurs in those involved in sports that require running and jumping. DIFFERENTIALSFemur Injuries and Fractures Knee Osteochondritis Dissecans Patellofemoral Joint Syndromes Pes Anserine Bursitis
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Ibuprofen (Motrin, Ibuprin) |
|---|---|
| Description | DOC for patients with mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis. |
| Adult Dose | 200-400 mg PO with food q4-6h while symptoms persist; not to exceed 3.2 g/d |
| Pediatric Dose | 5-10 mg/kg/dose PO q6-8h; not to exceed 40 mg/kg/24h |
| Contraindications | Documented hypersensitivity; peptic ulcer disease, recent GI bleeding or perforation, renal or hepatic insufficiency, or high risk of bleeding; ocular problems, granulocytopenia, and anemia may occur |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently; may increase serum levels of digoxin |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy |
| Drug Name | Ketoprofen (Orudis, Oruvail, Actron) |
|---|---|
| Description | For relief of mild to moderate pain and inflammation. Small dosages initially are indicated in small and elderly patients and in those with renal or liver disease. Doses over 75 mg do not increase therapeutic effects. Administer high doses with caution, and closely observe patient for response. |
| Adult Dose | 25-50 mg PO q6-8h prn; not to exceed 300 mg/d |
| Pediatric Dose | <3 months: Not established 3 months to 12 years: 0.1-1 mg/kg PO q6-8h >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in coagulation abnormalities or during anticoagulant therapy |
| Drug Name | Naproxen (Naprelan, Anaprox, Aleve, Naprosyn) |
|---|---|
| Description | For relief of mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing activity of cyclo-oxygenase, which results in a decrease of prostaglandin synthesis. |
| Adult Dose | 500 mg PO followed by 250 mg q6-8h; not to exceed 1.25 g/d |
| Pediatric Dose | <2 years: Not established >2 years: 2.5 mg/kg/dose PO; not to exceed 10 mg/kg/d |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug |
| Drug Name | Flurbiprofen (Ansaid) |
|---|---|
| Description | May inhibit cyclo-oxygenase enzyme, which in turn inhibits prostaglandin biosynthesis. These effects may result in analgesic, antipyretic, and anti-inflammatory activities. |
| Adult Dose | 200-300 mg/d PO divided bid/qid |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Category D in third trimester of pregnancy; acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug |
After the pain has resolved (which may take 6-24 mo), the patient may return to play as tolerated. The patient may need to participate less frequently, run at a slower speed, or decrease jumping activities. Premedicating or relying on NSAIDs regularly before or after competition is not advised. An intensive rehabilitation program of stretching exercises helps to decrease the likelihood of developing pain with vigorous sports activity. OSD usually resolves by the time the adolescent is aged 18 years.
The most common long-term complications are pain on kneeling as an adult and the cosmesis of a bony prominence on the anterior knee. Less common complications are the persistence of a painful ossicle requiring surgical excision and a displaced avulsion of a tibial tubercle.
Activity modification and regular stretching and strengthening exercises provide the best prevention.
The prognosis is excellent. OSD usually resolves by the time the patient is aged 18 years, when the tibial tubercle apophysis ossifies. The likelihood for long-term sequelae increases in severe cases, in cases in which treatment is not sought, or in cases in which the patient demonstrates poor compliance with the physician's recommendations.
OSD is a self-limited illness that resolves as the patient approaches adulthood. For acute flare-ups, anti-inflammatory medications, ice, elevation, and rest are recommended. For prevention, the patient should engage in activity and sports as tolerated without development of knee pain. Regular daily stretching and strengthening exercises should be performed to help prevent OSD. Inform patients regarding the activities that aggravate the condition and regarding the self-limiting nature of the disease.
For excellent patient education resources, visit eMedicine's Foot, Ankle, Knee, and Hip Center, Arthritis Center, and Bone Health Center. Also, see eMedicine's patient education article Knee Pain.
| Media file 1: Image courtesy of John T. Killion, MD; OSA Pediatric Orthopeaedics | |
![]() | View Full Size Image | Media type: Illustration |
| Media file 2: Image courtesy of John T. Killion, MD; OSA Pediatric Orthopeaedics | |
![]() | View Full Size Image | Media type: Illustration |
Osgood-Schlatter Disease excerpt
Article Last Updated: Apr 28, 2006